Bayers, Post-Xarelto

Bayer's Post-Xarelto Bridge Takes Shape as Sunharbo Shipments Near

Published on 11/17/2026 at 16:41 | Editorial boerse-global.de
Bayer plans mid-to-late November US shipments of newly FDA-approved Sunharbo as Jefferies says pipeline risk eased; Deutsche Bank lifts target to EUR 65.
Bayers, Post-Xarelto, Bridge, Takes, Shape, Sunharbo, Shipments, Near, Bayer, FDA-approved Illustration mit AI erstellt.

Bayer is lining up the first US shipments of its newly approved stroke medicine Sunharbo for mid-to-late November, a launch that analysts see as the most credible answer yet to the revenue hole left by Xarelto's patent expiry.

The FDA cleared the drug, whose active ingredient is asundexian, last week. The green light covers adults who have recently suffered a non-cardioembolic ischemic stroke or a high-risk transient ischemic attack, and it applies to the 50 mg dose given alongside an antiplatelet therapy. The approval rested on the Phase 3 OCEANIC-STROKE trial. Bayer has billed asundexian as the world's first approved factor XIa inhibitor.

Jefferies Sees Pipeline Risk Easing

Jefferies analyst Michael Leuchten said the US approval had substantially reduced the risk attached to Bayer's pharmaceutical pipeline. He kept his rating at "Hold," noting that his forecasts sit at the low end of the company's target range, and flagged the glyphosate litigation — particularly the looming global settlement — as a central focus of his valuation.

Deutsche Bank Research took a brighter view. In the past week it lifted its price target to EUR 65 from EUR 60 and reaffirmed its buy recommendation. Analyst Virginie Boucher-Ferte raised her estimates for EBITDA and earnings per share for 2027 and 2028, according to dpa-AFX.

Should investors sell immediately? Or is it worth buying Bayer?

Third-Quarter Beat Comes With an Upgraded Outlook

The analyst moves followed Bayer's early-November report for the third quarter of 2026, which showed group revenue of EUR 10.1 billion and EBITDA before special items of EUR 1.62 billion. Alongside those figures, the company raised its guidance for the Pharmaceuticals margin, group EBITDA before special items and free cash flow. For the full year 2026, Bayer now expects EBITDA before special items of EUR 9.8 billion to EUR 10.3 billion.

On the legal front, a US federal judge was reported yesterday to be reviewing which Roundup claims may proceed following a Supreme Court ruling — a examination that bears on the litigation landscape surrounding Monsanto's glyphosate-based herbicide and on how individual cases against Bayer move forward.

Shares Slip Without a Clear Trigger

The stock had drawn support earlier from the approval and from favorable glyphosate rulings, dpa-AFX reported. On the day of writing, the shares were down 1.2%, with the news agency citing no specific new company or analyst catalyst for the decline.

Bayer at a turning point? This analysis reveals what investors need to know now.

Investors will get the next full set of numbers when Bayer publishes its 2026 reporting on 24 February 2027.

Ad

Bayer Stock: New Analysis - 17 November

Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated Bayer analysis...

Disclaimer...
en | DE000BAY0017 | BAYERS | boerse | 70527675 |